Neoadjuvant chemotherapy combined with HER2-targeted therapy is now the standard neoadjuvant treatment regimen for HER2-positive breast cancer, and it has been shown to increase the pCR rate [8–12]. This evidence concerns the gene ERBB2 and breast cancer.